Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CTI Gets Italian Approval For Pixantrone
CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is in the process of preparing a
CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is in the process of preparing a
Cook Medical said that PMA submission is a critical step in the product development process, giving the FDA the appropriate information to evaluate the safety and efficacy of
Nexavar (sorafenib) tablets was evaluated in patients with advanced non-squamous non-small cell lung cancer (NSCLC). NExUS evaluated Nexavar versus placebo in combination with two chemotherapeutic agents, gemcitabine and
Patheon has posted a net income of $10.9m, compared to $0.5m for the prior year period. Operating income was $15m, compared to $13.4m for the prior year period.
Nesina, a highly selective DPP-4 inhibitor for the treatment of type 2 diabetes, has received regulatory approval from the Japanese Ministry of Health, Labour and Welfare on April
The data was presented during a presentation at the European Hematology Association (EHA) meeting being held June 10-13, 2010 in Barcelona, Spain. According to Allos, out of 54
Operating income for the current quarter was $240,000, compared to $704,000 for the same period last year. Net income was $199,000, or $0.01 per share, compared to $657,000,
The positive opinion for 2B3-101 by the COMP has specifically been granted for the treatment of glioma. As a proprietary brain-targeted version of the marketed product Caelyx/Doxil (PEG-liposomal
The advisory committee of FDA, that reviews and decides whether to approve a new treatment, has voted that FTY720 demonstrated substantial efficacy in treating relapsing remitting MS and
Cardium is expecting to initiate Generx clinical study in the second half of this year. The trial is expected to be a randomised, controlled, parallel-group, multicenter study to